Agennix's overall survival in doubt as placebo beats talactoferrin in Ph III NSCLC
13:20 EDT 7 Aug 2012 | SCRIP
The future of Agennix looks in doubt today after its oral recombinant lactoferrin product talactoferrin alfa failed to improve overall survival in a Phase III study in advanced non-small cell lung cancer (NSCLC) in patients who have received at leas..
Original Article: Agennix's overall survival in doubt as placebo beats talactoferrin in Ph III NSCLC
More From BioPortfolio on "Agennix's overall survival in doubt as placebo beats talactoferrin in Ph III NSCLC"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
